avelox 400 mg filmdragerad tablett
ebb medical ab - moxifloxacinhydroklorid - filmdragerad tablett - 400 mg - moxifloxacinhydroklorid 436,8 mg aktiv substans; laktosmonohydrat hjälpämne
moxifloxacin krka 400 mg filmdragerad tablett
krka sverige ab - moxifloxacinhydroklorid - filmdragerad tablett - 400 mg - moxifloxacinhydroklorid 454,75 mg aktiv substans - moxifloxacin
rivomoxi 400 mg filmdragerad tablett
rivopharm ltd. - moxifloxacinhydroklorid - filmdragerad tablett - 400 mg - moxifloxacinhydroklorid 436,43 mg aktiv substans; para-orange aluminiumlack hjälpämne
kymriah
novartis europharm limited - tisagenlecleucel - precursor b-cell lymphoblastic leukemia-lymphoma; lymphoma, large b-cell, diffuse - andra antineoplastiska medel - kymriah is indicated for the treatment of:• paediatric and young adult patients up to and including 25 years of age with b cell acute lymphoblastic leukaemia (all) that is refractory, in relapse post transplant or in second or later relapse. • adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl) after two or more lines of systemic therapy. • adult patients with relapsed or refractory follicular lymphoma (fl) after two or more lines of systemic therapy.
moxifloxacin 2care4 400 mg filmdragerad tablett
2care4 aps - moxifloxacinhydroklorid - filmdragerad tablett - 400 mg - moxifloxacinhydroklorid 454,75 mg aktiv substans
moxifloxacin abacus medicine 400 mg filmdragerad tablett
abacus medicine a/s - moxifloxacinhydroklorid - filmdragerad tablett - 400 mg - moxifloxacinhydroklorid 454,75 mg aktiv substans
moxifloxacin fresenius kabi 400 mg/250 ml infusionsvätska, lösning
fresenius kabi ab - moxifloxacinhydroklorid - infusionsvätska, lösning - 400 mg/250 ml - moxifloxacinhydroklorid 437,5 mg aktiv substans - moxifloxacin
moxifloxacin orion 400 mg filmdragerad tablett
orion corporation - moxifloxacinhydroklorid - filmdragerad tablett - 400 mg - mannitol hjälpämne; moxifloxacinhydroklorid 436,37 mg aktiv substans
ebvallo
pierre fabre medicament - tabelecleucel - lymphoproliferative disorders - ebvallo is indicated as monotherapy for treatment of adult and paediatric patients 2 years of age and older with relapsed or refractory epstein-barr virus positive post-transplant lymphoproliferative disease (ebv+ ptld) who have received at least one prior therapy. for solid organ transplant patients, prior therapy includes chemotherapy unless chemotherapy is inappropriate.
ciprofloxacin navamedic 2 mg/ml infusionsvätska, lösning
navamedic asa - ciprofloxacin - infusionsvätska, lösning - 2 mg/ml - glukosmonohydrat hjälpämne; ciprofloxacin 2 mg aktiv substans - ciprofloxacin